Vancomycin-Associated Nephrotoxicity
Status: | Completed |
---|---|
Conditions: | Nephrology |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/2/2016 |
Start Date: | November 2010 |
End Date: | April 2011 |
Contact: | Vanessa Stevens, PhD |
Email: | vstevens@buffalo.edu |
Phone: | (585) 273-3526 |
Occurrence and Economic Impact of Nephrotoxicity Associated With Vancomycin Exposure
The primary goal of this study is to determine if there is an association between greater
exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to
estimate the costs to the hospital associated with these nephrotoxic events.
exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to
estimate the costs to the hospital associated with these nephrotoxic events.
Inclusion Criteria:
- 18 years or older at time of hospital admission
- Had an absolute neutrophil count of ≥ 1000 cells/mm^3
- Received > 48 hours of intravenous vancomycin therapy
- Had one or more vancomycin trough levels reported within the 96 hours after therapy
initiation
- Had a baseline serum creatinine level of < 2.0 mg/dL and baseline creatinine
clearance level of ≥ 30 mL/min
Exclusion Criteria:
- Previous diagnosis of cystic fibrosis
We found this trial at
1
site
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
